BioCryst Pharmaceuticals, Inc. (BCRX)
NEUTRALFundamental
63
मूल्य
$9.81
मार्केट कैप
$2.43B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$941M
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$-385M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$345M
कुल इक्विटी
$-119M
कुल देनदारियाँ
$633M
Current Ratio
2.32
Interest Coverage
4.16
Debt/EBITDA
1.20
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$26.93
वर्तमान मूल्य
$9.81
Margin of Safety
+63.6%
Fair Value सीमा
$20.10 - $33.76
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
7.86
ROE
-221.4%
P/B Ratio
-
P/FCF
6.62
Gross Margin
97.8%
ROIC
-70.9%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-70.9%
WACC
9.0%
ROIC − WACC
-79.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (13)
- EPS shows upward trend
- Gross Margin 97.8%
- P/FCF 6.62
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Low reliance on intangibles
- DCF valuation (Undervalued)
- Revenue Growth 5Y 117.9%
- Analyst Consensus 88% Buy
- Piotroski F-Score 7/9
फेल (8)
- Price CAGR 4.20%
- ROIC -70.9%
- Operating Margin -33.3%
- Return on Tangible Assets
- ROE -328.8%
- Earnings Surprise avg -35.2%
- Share Dilution 5.5%
- Net Margin Trend -40.9% vs -6.4%
अनुपलब्ध (6)
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 54 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 46 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 59 |
| Mr. John Ruesch | Chief Technical Operations Officer | - |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | - |
| Nick Wilder | Manager of Investor Relations | - |
| Ms. Stephanie Angelini | Chief People Officer & Chief Communications Officer | - |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 70 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 72 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | - |
Audit जोखिम
8
बोर्ड जोखिम
3
मुआवजा जोखिम
10
शेयरधारक अधिकार जोखिम
8
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for BCRX, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. The transcript, which is available for review, details the company's financial performance and strategic outlook for the first quarter of 2026. Investors and analysts can access the full transcript to gain insights into the company's operational updates, pipeline progress, and future guidance. As this is an informational event, no immediate market reaction is implied without further specific financial data or forward-looking statements being disclosed within this summary.
via Markets Gazette